Theophylline Extended-Release Tablets, 100 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-500-10 Recall

Ongoing
Drugs
Class II — Moderate

Recall Date

Nov 4, 2026

Company

Brandywine Pharmaceuticals, LLC

Source

FDA

Units

1,620 100-count bottles

Reason: CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory

Class II: Use of the product may cause temporary or medically reversible health problems.

Official FDA recall notice

Information is from official FDA notices. Do not stop taking any medication without consulting your doctor or pharmacist first — the risks of stopping may be greater than the risk from the recalled product.

Recall Details

Description

CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory

Reason for Recall

CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory

Product: Theophylline Extended-Release Tablets, 100 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-500-10
Official Recall ID: FDA-DRUG-D-0110-2027
Units affected: 1,620 100-count bottles

What Should I Do?

Check your lot number. Don't stop taking a prescribed medication without talking to your pharmacist or doctor. Contact the pharmacy where you got it about a replacement.

Quantity: 1,620 100-count bottles

Remediation GuideAction Required

5-step guide to help you action required this recalled product. Click Start Remediation to track your progress.

1
Confirm Your Product Is Affected
2
Read the Full Recall Notice
3
Stop Using the Product if in Doubt

+2 more steps…

View Official Recall Notice (FDA)

Last updated November 10, 2026

Injured by a recalled product?

Our legal partners offer free consultations for recall victims.

Get Free Legal Help →Sponsored

Stay Informed

Weekly recall digest — free, no spam.